ALTME Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
TME Pharma N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.071 |
| 52 Week High | €0.44 |
| 52 Week Low | €0.061 |
| Beta | 1.58 |
| 1 Month Change | -1.94% |
| 3 Month Change | -52.09% |
| 1 Year Change | -77.13% |
| 3 Year Change | -99.65% |
| 5 Year Change | -99.84% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| ALTME | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -6.7% | 4.8% | 2.7% |
| 1Y | -77.1% | -21.9% | 3.5% |
Return vs Industry: ALTME underperformed the French Biotechs industry which returned -21.9% over the past year.
Return vs Market: ALTME underperformed the French Market which returned 3.5% over the past year.
Price Volatility
| ALTME volatility | |
|---|---|
| ALTME Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 10.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALTME's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALTME's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 13 | Aram Mangasarian | www.tmepharma.com |
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. The company is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.
TME Pharma N.V. Fundamentals Summary
| ALTME fundamental statistics | |
|---|---|
| Market cap | €6.67m |
| Earnings (TTM) | -€6.32m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs ALTME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTME income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €6.33m |
| Earnings | -€6.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.067 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALTME perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 14:01 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TME Pharma N.V. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jean-Pierre Loza | In Extenso Financement & Marché |
| Benjamin Isaacson | Scotiabank Global Banking and Market |